This promotional website is for UK Healthcare Professionals involved in the management of haematological malignancies. Adverse event reporting information can be found below.
Welcome to VENCLYXTO in CLL
Discover a wealth of data, practical information and resources to support your understanding and use of chemo-free, fixed-duration, VENCLYXTO-based treatment in the management of patients with CLL.1
FRONTIERS is a programme of AbbVie promotional events and resources for UK HCPs involved in the management of haematological malignancies.
Develop your knowledge with FRONTIERS events, insights and resources
Learn from leading CLL experts and practice pioneers
VENCLYXTO (venetoclax) has three licenced indications for CLL1
VENCLYXTO in combination with obinutuzumab (VEN+O) is indicated for the treatment of adult patients with previously untreated CLL
VENCLYXTO in combination with rituximab (VEN+R) is indicated for the treatment of adult patients with CLL who have received at least one prior therapy
VENCLYXTO is licensed as monotherapy (VEN mono), for the treatment of adult patients with CLL:
- in the absence of del(17p) or TP53 mutations and who have failed both chemoimmunotherapy and a BCRI
- in the presence of del(17p) or TP53 mutations and who are either unsuitable for, or have failed a BCRI
BCRi, B-cell receptor pathway inhibitor; CLL, Chronic lymphocytic leukaemia; HCP, Healthcare professional; del(17p), 17p deletion; R/R, Relapsed/refractory; TP53, Tumour protein 53.
References
- VENCLYXTO Summary of Product Characteristics.
You are advised to read the Prescribing Information and Summary of Product Characteristics to evaluate patient suitability for VENCLYXTO.
VENCLYXTO PRESCRIBING INFORMATION
VENCLYXTO SUMMARY OF PRODUCT CHARACTERISTICS (GB)
VENCLYXTO SUMMARY OF PRODUCT CHARACTERISTICS (NI)
UK-VNCCLL-230492. Date of preparation: April 2024.
